FDA Approves New Drug Treatment for Hospitalized COVID-19 Patients

Innovation Pharmaceuticals announced that the U.S. FDA had approved the Company’s Investigational New Drug application to proceed with the Phase 2 clinical trial of Brilacidin in hospitalized patients with COVID-19.

Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 supports its potential to inhibit emerging coronavirus mutations (variants), such as those in the United Kingdom, Denmark, and South Africa.

"Even with vaccines starting to be rolled out, it will be many more months for them to reach the masses and potentially years before vaccines are available worldwide,” commented Leo Ehrlich, CEO at Innovation Pharmaceuticals, in a press statement. “We have great hopes Brilacidin will emerge as a novel therapeutic to help fight the global pandemic.”